BioSpace News Archive

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will participate in two upcoming investor conferences. On Wednesday, January 13, at 2:00 p.m. ET, Fred P. Lampropoulos, President and Chief Executive Offic

- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy , CEO, will participate in pre-recorded presentations at the following virtual investor con

With massive jumps in the domain of healthcare software development coupled with the escalating number of patients suffering from chronic health disorders, the healthcare IT market share is making significant strides globally.

Aspen RxHealth, whose first of its kind clinical pharmacy model developed by pharmacists for pharmacists delivers value for health plans and risk-bearing providers, announced the closure of a $23 million Series B funding round led by Bessemer Venture Partners.

Tidepool, a 5013 nonprofit, announced completion of its FDA submission of Tidepool Loop, an automated insulin dosing app intended for the management of type 1 diabetes.

Repertoire Immune Medicines, a clinical-stage biotech company creating a new category of immune therapies for cancer, autoimmunity and infectious disease, today announced that John Cox, Chief Executive Officer, will participate in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 8:05 a.m. EST

Evotec SE announced that its management will be presenting at and attending the following upcoming conferences in the first quarter of 2021:

SIFI, a leading international ophthalmic company, announces the launch of SYNFO, a novel medical device representing the latest addition to its comprehensive dry eye portfolio.

Mileutis Ltd. (“Mileutis”), an Israeli biopharmaceutical company which helps mitigate the use of antibiotics in animals through its safe and residue-free immunomodulator peptides, today announced that its CEO, David Javier Iscovich is set to present a corporate presentation at the 39th Annual J.P. Morgan Healthcare Conference.

First Dedicated Device to Enable Coronary Access and Prevent Coronary Obstruction During Transcatheter Aortic Valve Replacement